LSE - Delayed Quote GBp

Hemogenyx Pharmaceuticals Plc (HEMO.L)

177.90

-0.85

(-0.47%)

As of 2:47:26 PM GMT+1. Market Open.

Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol

Amendment to Clinical Protocol for HG-CT-1 to Include Pediatric Patients with R/R AML LONDON, UNITED KINGDOM / ACCESS Newswire / May 14, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has filed an amendment to the clinical ...

ACCESS Newswire yesterday

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director’s Dealing

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT ...

ACCESS Newswire 7 days ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Second Patient Treated with HG-CT-1 CAR-T Therapy

LONDON, GB / ACCESS Newswire / May 2, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company's ongoing Phase I clinical trial of HG-CT-1, its proprietary ...

ACCESS Newswire 13 days ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Final Results

LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 ...

ACCESS Newswire 17 days ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces FDA Annual Report

Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML LONDON, UK / ACCESS Newswire / April 3, 2025 /Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has submitted its Annual Report to the ...

ACCESS Newswire last month

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

LONDON, GB / ACCESS Newswire / March 31, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 ...

ACCESS Newswire last month

HOPHF
Hemogenyx Pharmaceuticals PLC Announces First Patient Safety

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF ...

ACCESS Newswire last month

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials

Recruitment of Second Patient for HG-CT-1 Clinical Trial LONDON, GB / ACCESS Newswire / March 17, 2025 /Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary ...

ACCESS Newswire last month

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment

Institutional backing of £709,200 for continuing Phase 1 Clinical Trials LONDON, UNITED KINGDOM / ACCESS Newswire / March 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) ("Hemogenyx Pharmaceuticals" or the "Company") is pleased to announce ...

ACCESS Newswire 2 months ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF ...

ACCESS Newswire 2 months ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £340,000 through the issue of 100,000 new ordinary shares ("Placing Shares") at a price of 340p per share (the "Placing"). One institutional investor has subscribed ...

ACCESS Newswire 4 months ago

HOPHD
Hemogenyx Pharmaceuticals PLC Announces Opening of First Clinical Site

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) is pleased to announce the opening of the first clinical site for its lead asset, HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults. ...

ACCESS Newswire 4 months ago

HOPHD
Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T Manufacturing

LONDON, UNITED KINGDOM / ACCESSWIRE / December 19, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood malignancies, and Kure.ai ("Kure"), a leader in ultrafast CAR-T manufacturing ...

ACCESS Newswire 4 months ago

HOPHD
Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, wishes to provide a further update on the admission of the New Ordinary Shares ...

ACCESS Newswire 5 months ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Site Initiation Visit Completed

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, is pleased to announce the successful completion of the Site Initiation Visit at the first clinical site for its Phase I clinical ...

ACCESS Newswire 5 months ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces CBR Macrophage Delivery Update

Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development LONDON, UK / ACCESSWIRE / December 6, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical company, is pleased to announce ...

ACCESS Newswire 5 months ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Notice of Extraordinary General Meeting Proposed Capital Reorganisation and New Articles of Association LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals ...

ACCESS Newswire 5 months ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company developing innovative therapies ...

ACCESS Newswire 5 months ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial Opening

Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company focused on developing ...

ACCESS Newswire 6 months ago

HOPHF
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC

Prevail Partners, LLC to invest again in Hemogenyx Pharmaceuticals Prevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical study LONDON, UNITED KINGDOM / ACCESSWIRE / October 2, 2024 / Hemogenyx ...

ACCESS Newswire 7 months ago

HOPHF

Performance Overview

Return	HEMO.L	FTSE 100 (^FTSE)
YTD	-56.07%	+5.34%
1-Year	-71.49%	+1.94%
3-Year	-67.65%	+16.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hemogenyx Pharmaceuticals Plc (HEMO.L)

Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol

Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director’s Dealing

Hemogenyx Pharmaceuticals PLC Announces Second Patient Treated with HG-CT-1 CAR-T Therapy

Hemogenyx Pharmaceuticals PLC Announces Final Results

Hemogenyx Pharmaceuticals PLC Announces FDA Annual Report

Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Hemogenyx Pharmaceuticals PLC Announces First Patient Safety

Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials

Hemogenyx Pharmaceuticals PLC Announces Institutional Investment

Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1

Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000

Hemogenyx Pharmaceuticals PLC Announces Opening of First Clinical Site

Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T Manufacturing

Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN

Hemogenyx Pharmaceuticals PLC Announces Site Initiation Visit Completed

Hemogenyx Pharmaceuticals PLC Announces CBR Macrophage Delivery Update

Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial Opening

Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC

Performance Overview